Investing15d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product. The analyst ...
Investing15d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.
EurekAlert!16d
Up to half of Medicare beneficiaries lack financial resources to pay for a single hospital stay
quality-adjusted life-years (QALYs), and costs among patients using established screening methods of fecal immunochemical tests (FIT), colonoscopies or multitarget stool DNA test (Exact Sciences ...
Stockhouse16d
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
Exact Sciences will also present new data on improving adherence to help close the gap in CRC screening. ACG abstracts are available on the meeting website. “Exact Sciences is pleased to share new ...
kalkinemedia17d
Exact Sciences (NASDAQ: EXAS) Showcases Cologuard Plus™ Effectiveness at ACG Annual Meeting
Highlights:,Cologuard Plus™ outperforms other noninvasive screening tests in life-years gained and reduces the need for colonoscopies.,High adherence rates, particularly among Spanish-speaking ...